Panelists stress that timely and accurate diagnosis of KMT2A-rearranged acute myeloid leukemia (AML) is essential for personalized treatment planning, highlighting the need to overcome systemic delays ...

Flow cytometry–triggered genomic testing and automation reduced turnaround times for AML diagnostics, enhancing personalized therapy and patient care. The initiative involved clinician education, a ...

The classification of AML and therapeutic options are now largely driven by genetically defined subtypes. Personalization of treatment relies on timely completion and reporting of cytogenetic and ...

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, announced today the launch of AML Express, a next-generation sequencing (NGS) assay ...

Examining protein changes in peripheral blood cells just 24 hours after initiating chemotherapy for acute myeloid leukemia (AML) could predict 5-year overall survival, potentially allowing treatment ...

A highly sensitive bone marrow test could double survival rates for some groups of younger adults with acute myeloid leukemia (AML) by helping doctors identify if they might relapse up to three months ...

A simple blood test capable of detecting trace levels of leukaemia cells remaining after intensive chemotherapy has been developed by scientists at the National Institute for Health Research (NIHR) ...

Acute myeloid leukemia (AML) is not hereditary, but a person may inherit gene mutations that make the condition more likely. Having a close family member with AML can also increase the risk. Acute ...